Zencore Biologics

Executive Summary

Zencore Biologics is a China-based independent Contract Development and Manufacturing Organization (CDMO) that provides end-to-end CMC services for biologics, with a focus on oncology and immunology therapeutics. Founded in 2017 and headquartered in Shanghai, the company has raised $225 million and employs 500-1000 staff. Its core capabilities include mammalian cell culture, process development, analytical services, and GMP manufacturing for antibodies and Antibody-Drug Conjugates (ADCs), leveraging both single-use and stainless steel bioreactors up to 5,000L. The company's dedicated ADC platform positions it as a key player in the rapidly growing ADC CDMO market, particularly for global biopharma seeking high-quality, cost-effective manufacturing solutions in Asia.

Upcoming Catalysts (preview)

• Q3 2026Expansion of commercial-scale manufacturing capacity with new 5,000L bioreactor suite85% success
• Q2 2026Strategic partnership with a top-20 pharma for ADC development and manufacturing60% success
• Q4 2026Potential Series C funding or IPO announcement to fuel global expansion50% success